Boston Scientific Corporation (NYSE:BSX) insider Valley Gold Master Fund L. Sun acquired 27,431 shares of the business’s stock in a transaction dated Friday, December 1st. The stock was bought at an average cost of $0.44 per share, with a total value of $12,069.64.

Boston Scientific Corporation (NYSE:BSX) opened at $24.90 on Tuesday. Boston Scientific Corporation has a 1 year low of $20.36 and a 1 year high of $29.93. The company has a debt-to-equity ratio of 0.58, a quick ratio of 0.50 and a current ratio of 0.72. The stock has a market capitalization of $35,909.07, a PE ratio of 21.43, a PEG ratio of 2.02 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The company had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.21 billion. During the same period last year, the company earned $0.27 earnings per share. The firm’s revenue was up 5.6% compared to the same quarter last year. research analysts predict that Boston Scientific Corporation will post 1.25 EPS for the current fiscal year.

A number of equities research analysts recently weighed in on BSX shares. SunTrust Banks set a $33.00 price target on Boston Scientific and gave the company a “buy” rating in a research note on Monday. Cowen set a $31.00 price target on Boston Scientific and gave the company a “buy” rating in a research note on Thursday, November 30th. BMO Capital Markets reiterated a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a research report on Wednesday, November 29th. BTIG Research upgraded Boston Scientific from a “neutral” rating to a “buy” rating and set a $31.00 price objective on the stock in a research report on Thursday, November 30th. Finally, J P Morgan Chase & Co reiterated a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $30.56.

Several institutional investors and hedge funds have recently modified their holdings of the company. NGAM Advisors L.P. increased its holdings in Boston Scientific by 12.4% in the second quarter. NGAM Advisors L.P. now owns 49,840 shares of the medical equipment provider’s stock worth $1,382,000 after purchasing an additional 5,513 shares in the last quarter. Janney Montgomery Scott LLC increased its holdings in shares of Boston Scientific by 1.8% during the second quarter. Janney Montgomery Scott LLC now owns 53,602 shares of the medical equipment provider’s stock valued at $1,486,000 after acquiring an additional 929 shares in the last quarter. CIBC Asset Management Inc increased its holdings in shares of Boston Scientific by 0.5% during the second quarter. CIBC Asset Management Inc now owns 129,853 shares of the medical equipment provider’s stock valued at $3,600,000 after acquiring an additional 689 shares in the last quarter. IFP Advisors Inc increased its holdings in shares of Boston Scientific by 30.4% during the second quarter. IFP Advisors Inc now owns 9,077 shares of the medical equipment provider’s stock valued at $252,000 after acquiring an additional 2,114 shares in the last quarter. Finally, Retirement Systems of Alabama increased its holdings in shares of Boston Scientific by 0.3% during the second quarter. Retirement Systems of Alabama now owns 1,404,418 shares of the medical equipment provider’s stock valued at $38,930,000 after acquiring an additional 4,875 shares in the last quarter. Institutional investors own 90.57% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/05/boston-scientific-corporation-bsx-insider-valley-gold-master-fund-l-sun-purchases-27431-shares.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific Corporation and related stocks with our FREE daily email newsletter.